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Abstract
Background: A disintegrin and metalloprotease 12 (ADAM12-S) has previously been reported to be significantly
reduced in maternal serum from women with fetal aneuploidy early in the first trimester and to significantly
improve the quality of risk assessment for fetal trisomy 21 in prenatal screening. The aim of this study was to
determine whether ADAM12-S is a useful serum marker for fetal trisomy 21 using the mixture model.
Method: In this case control study ADAM12-S was measured by KRYPTOR ADAM12-S immunoassay in maternal
serum from gestational weeks 8 to 11 in 46 samples of fetal trisomy 21 and in 645 controls. Comparison of
sensitivity and specificity of first trimester screening for fetal trisomy 21 with or without ADAM12-S included in the
risk assessment using the mixture model.
Results: The concentration of ADAM12-S increased from week 8 to 11 and was negatively correlated with
maternal weight. Log MoM ADAM12-S was positively correlated with log MoM PAPP-A (r = 0.39, P < 0.001), and
with log MoM free beta hCG (r = 0.21, P < 0.001). The median ADAM12-S MoM in cases of fetal trisomy 21 in
gestational week 8 was 0.66 increasing to approx. 0.9 MoM in week 9 and 10. The use of ADAM12-S along with
biochemical markers from the combined test (PAPP-A, free beta hCG) with or without nuchal translucency
measurement did not affect the detection rate or false positive rate of fetal aneuploidy as compared to routine
screening using PAPP-A and free b-hCG with or without nuchal translucency.
Conclusion: The data show moderately decreased levels of ADAM12-S in cases of fetal aneuploidy in gestational
weeks 8-11. However, including ADAM12-S in the routine risk does not improve the performance of first trimester
screening for fetal trisomy 21.
Background
The soluble form of A disintegrin and metalloprotease
12 (ADAM12-S) with suggested proteolytic activity on
Insulin-like growth factor binding protein (IGFBP) - 3
and 5 and the epidermal growth factor ligands EGF,
Betacellulin and HB-EGF [1], is synthesized by the pla-
centa syncytiotrophoblasts [2,3] and is present in high
concentrations in maternal serum from early first trime-
ster [4-6]. Since ADAM12-S was first reported to be sig-
nificantly reduced in maternal serum from women with
fetal trisomy 21 [4] much attention has been given to
investigating the utility of ADAM12-S as a prenatal
marker for fetal aneulpoidy in first and second trimester
[4-9], fetal pre-eclampsia [10,11] and intra uterine
growth restriction [12]. The discriminatory efficiency of
ADAM12-S as a marker for fetal aneuploidy in first tri-
mester has been inconclusive. Reported median multiple
of median (MoM) for maternal serum ADAM12-S in
mothers with fetal trisomy 21 in first trimester have ran-
ged from being substantially lower than those in unaf-
fected pregnancies to showing relatively small
reductions. Laigaard et al., first reported a median
ADAM12-S MoM value of just 0.140 among 18 cases of
trisomy 21, collected largely before 10 weeks gestation
[4]. Screening algorithms that included ADAM12-S in
addition to both maternal age and first trimester bio-
chemistry and maternal age, biochemistry and NT
showed that ADAM12-S was a potentially valuable
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addition to first trimester screening. Subsequent studies
[4,13-15], which have included serum samples collected
both early and late in the first trimester, have suggested
that ADAM12-S is less promising as an effective marker
for fetal trisomy 21. Median ADAM12-S MoM values
for trisomy 21 pregnancies in these studies are largely
inconsistent with the initial findings of Laigaard et. al.,
and show a moderate to negligible reduction relative to
unaffected MoM values; ranging from 0.61 MoM [16]
among samples collected before 10 weeks gestation, to
0.977 MoM [15] between 11 and 13 weeks gestation.
Large variation in the reported ADAM12-S MoM values
and in screening test results has failed to confirm the
utility of ADAM12-S as a prenatal marker, either alone
or combined with pregnancy-associated plasma protein-
A (PAPP-A) and maternal serum free beta-human chor-
ionic gonadotropin (free beta-hCG) and in conjunction
with Nuchal Translucency (NT). Whether the diversity
in published results represents differences in preanalyti-
cal handling of clinical samples [13] and/or immunoas-
say performance remains to be investigated.
In order to develop further our understanding of
ADAM12-S as a marker for fetal aneuploidy in first tri-
mester and to determine the clinical potential of this
marker in routine screening for fetal trisomy 21, we
have examined the maternal serum concentration of
ADAM12-S using a newly developed immunoassay in
46 samples of maternal serum from women with fetal
trisomy 21, and 645 controls in gestational week 8-11.
Methods
Serum samples
This was a case-control study using samples that were
collected as part of the nationwide prenatal screening
program in Denmark. Blood samples were drawn by
family general practitioners (GPs) as part of the routine
first trimester screening program from gestational week
8+0 to 13+6. Serum was isolated and sent to the
Department of Clinical Biochemistry at Aarhus Univer-
sity Hospital - Skejby for analysis. All samples were
stored at -80°C and were thawed prior to analysis of
ADAM12-S. 46 samples of maternal serum from geneti-
cally verified fetal trisomy 21 between gestational week
8+1 and 11+6 were analysed. 42 of these were identified
by the routine first trimester risk assessment program
based on preclinical risk, PAPP-A, free b-hCG and NT
using a risk cut-off of 1 in 300 at the time of analysis. 4
cases of fetal trisomy 21 were not identified by the pre-
natal screening program and resulted in live-born
infants. As a control group 645 samples of maternal
serum from mothers from gestational week 8+0 to 11+6
with unaffected spontaneous conceived, singleton preg-
nancies from non-diabetic mothers with different parity
were used. Data collected on maternal characteristics
included maternal weight, smoking status and ethnicity;
all women were Caucasian, non-smokers. PAPP-A and
free b-hCG results determined by the Brahms KRYP-
TOR assay were available on all samples. Ultrasound
examination was performed during gestational weeks 11
+ 2 to 13 + 6. Gestational age was determined by mea-
surement of CRL using the formula obtained by Robin-
son [17], and the gestational age at time of blood
sampling was calculated accordingly. Only blood sam-
ples with a gestational age between 8+0 and 11+6 were
used for the study. The mean maternal ages were 31
years (controls) and 35 years (trisomy 21). The use of
samples for the purpose of method development in first
trimester screening has been approved by the Danish
Central Biomedical Research Ethics Committee, Journal
No. 2006-7041-88.
Assay procedures, antibodies, standards and controls and
testing
Serum ADAM12-S was measured using the Brahms
KRYPTOR using a newly developed assay for the pur-
pose of routine biochemical screening (Cezanne SAS,
Nimes, France). The assay was set up a homogenous
sandwich fluoroimmunoassay using time resolved ampli-
fied cryptate emission (TRACE) technology [18]. In the
assay, purified anti-human ADAM12-S rat monoclonal
antibodies of clones 41R and 29R were coupled to
AF647 fluorophore (Invitrogen, San Diego, CA) and to
europium cryptate TBP-Di-SMP (Cis Bio International
SAS, Saclay, France), respectively.
Controls were prepared from a third-trimester serum
pool diluted (495 μg/L and 2295 μg/L) in horse serum
(Sigma H 1138). We calibrated a third-trimester serum
pool against recombinant ADAM12-S, and used the pool
to generate a standard curve for determining ADAM12-S
concentrations. The KRYPTOR ADAM12-S has an assay
range of 240 to 10 267 μg/L and the dilution curves are
linear in this concentration range (r2 > 0.99). The mean
recovery of concentrated ADAM12-S added to serum
samples was 109% (range 102-118%, n = 4). Intra-assay
variation was determined to be 5.2%. The average inter-
assay variations in 6 runs were from 1.8% to 7.7%.
Statistics
Multiple regression modelling of log transformed
ADAM12-S, PAPP-A and free b-hCG concentrations
was used to obtain log MoM values specific to gesta-
tional age and maternal weight. Adequacy of fit was
assessed using diagnostic plots of MoM values.
Screening performance results are based on patient-
specific risks for trisomy 21, calculated from the product
of the maternal age-related risk and the likelihood ratio
(LR) for the appropriate combination of biochemical
markers.
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Where NT has been included in the screening algo-
rithm, the patient-specific risks have been calculated by
multiplying the maternal age-related risk by the LR for
the biochemistry and the LR for NT, as defined in the
mixture model [19].
Empirical screening performance results include
maternal age standardised detection and false-positive
rates (with 95% confidence intervals) for tests incorpor-
ating (i) PAPP-A and free beta-hCG, (ii) PAPP-A, free
beta-hCG and ADAM12-S, (iii) PAPP-A, free beta-hCG
Figure 1 ADAM12 concentration in serum is dependent on Maternal Weight. Log ADAM12-S concentration (μg/l) in maternal serum from
645 controls by gestation (top panel) and by weight (bottom panel). The superimposed lines correspond to the fitted relationship from the
multiple regression model log ADAM12-S = 2.9530 + 0.01454 (gestational age (days) - 77) - 0.002421 (maternal weight - 69). The median
maternal weight (67 kg) and median gestational age (66 days) have been used to obtain the fitted lines on the top and bottom panels
respectively.
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Figure 2 Biochemical markers in unaffected pregnancies. Diagnostic plots for ADAM12-S, PAPP-A and free b hCG MoM values in unaffected
pregnancies.
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and NT, (iv) PAPP-A, free beta-hCG, NT and
ADAM12-S, (v) PAPP-A and ADAM12-S and (vi)
PAPP-A, ADAM12-S and NT, for risk cut-offs of 1 in
100 and 1 in 250 at the time of screening. The maternal
age distribution of England and Wales in the three years
from 2000 to 2002 [20] was used as a reference for esti-
mating the standardised rates.
Modelled screening performance results are based on
the simulation of 100 000 unaffected and 100 000 tris-
omy 21 pregnancies with the 2000 to 2002 maternal age
distribution of England and Wales, NT distributions
according to the mixture model and distributions of log
MoM ADAM12-S, log MoM PAPP-A and log MoM
free b-hCG derived from the data.
Results
ADAM12-S was analysed in 46 cases of fetal trisomy 21
and 645 controls between gestational age 8+0 and 11+6.
In the controls the median concentration (μg/l) of
ADAM12-S increased throughout the three weeks. Fig-
ure 1 shows the relationship between ADAM12-S and
gestational age (top panel) and ADAM12-S and mater-
nal weight (bottom panel). Multiple regression analysis
showed significant effects (P < 0.001) on the concentra-
tion of ADAM12-S from both gestational age and
maternal weight and the fitted relationship from the
multiple regression model is superimposed on the plots
in Figure 1. The median MoM values for ADAM12-S,
PAPP-A and free beta-hCG at 8 to 11 weeks gestation
and for maternal weight show an adequate model fit in
each case (Figure 2).
The correlations between log MoM ADAM12-S,
PAPP-A and free bhCG in unaffected pregnancies (by
gestational week) and in trisomy 21 pregnancies are
given in Table 1. Notable features of Table 1 are the
strong positive correlations between log MoM
ADAM12-S and log MoM PAPP-A in the control preg-
nancies, with minimal variation across gestational age,
and the significant positive correlation (r = 0.33, P <
0.03) between log MoM ADAM12-S and log MoM
PAPP-A in trisomy 21 pregnancies.
There was a general decrease in concentration of
ADAM12-S in cases of fetal aneoploidy compared to the
controls with similar gestational age at time of blood
sampling. The median ADAM12-S MoM of the trisomy
21 cases was 0.66 in gestational week 8 increasing to
0.95 in week 9 and 0.85 in week 10, with standard
deviations between 0.11 and 0.16 (Table 2). Log MoM
ADAM12-S values in the fetal trisomy 21 cases was
described by the linear regression: log MoM ADAM12-S
= -0.004227 + 0.007818 × (gestational age (days) - 77).
The detection rates and false-positive rates from
including and excluding ADAM12-S, for risk cut-offs of
1 in 100 and 1 in 250 at time of screening, are given in
Table 3. Table 4 shows detection rates for a fixed false-
positive rate of 5%. These have been, standardised to a
reference maternal age population (UK 2000 to 2002).
The corresponding modelled results using the para-
meter estimates from the data and assuming the fitted
multivariate Guassian distributions are given in Tables 5
and 6.
Including ADAM12-S in the risk calculations affects
neither the detection rate nor the false positive rate at
fixed risk cut offs of 1 in 100 and 1 in 250, and with a
Table 1 Correlations between biochemical markers in
first trimester screening
Controls trisomy 21
cases
gestational
week
correlation correlation
ADAM12-S and PAPP-A 8 0.40
9 0.34
10 0.43
Overall 0.39 0.33
ADAM12-S and free b-
hCG
8 0.30
9 0.10
10 0.28
Overall 0.21 -0.02
Correlations between log MoM ADAM12-S and PAPP-A and log MoM
ADAM12-S and free b-hCG in unaffected pregnancies (by gestational week)
and in trisomy 21 pregnancies.
Table 2 ADAM12 Median MoM in Cases (fetal trisomy 21) and Controls
Weeks Controls median MoM SD
(95% CI)
n Trisomy 21 median MoM SD
(95% CI)
n
8+0 to 8+6 0.992 0.173
(0.158 - 0.190)
217 0.664 0.158
(0.118 - 0.241)
17
9+0 to 9+6 1.008 0.173
(0.158 - 0.190)
229 0.945 0.143
(0.107 - 0.214)
18
10+0 to 10+6 1.003 0.153
(0.139 - 0.170)
191 0.848 0.111
(0.078 - 0.195)
11
11+0 to 11+6 0.932 0.147(0.100-0-299) 8 - - -
Median MoM and SD log MoM ADAM12-S in controls (n = 645) and trisomy 21 cases (n = 46) in gestational week 8 to 11.
SD: standard deviation, CI: confidence interval.
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fixed false positive rate both with and without inclusion
of NT in the risk calculations. Exchanging free bhCG
with ADAM12-S also did not affect the performance of
the risk assessment.
Discussion
The results of this study show that ADAM12-S has little
value as a marker of fetal trisomy 21 early in first trime-
ster from gestational age 8+0 to 11+0. We used the
KRYPTOR ADAM12-S assay which has not previously
been validated for this purpose. The present assay is
based on the TRACE® technology, employing two anti-
bodies that recognized two different epitopes in disinte-
grin domain of the ADAM12-S molecule. The results
show a high reproducibility with SD log MoM values
around 0.15-0.17 for the controls and 0.11 to 0.16 for
the cases. This performance is in agreement with pre-
vious data [21].
The results show an increase in the concentration of
ADAM12-S over the three weeks, which has previously
been reported using other assays [5,6]. However the
absolute concentrations of ADAM12-S determined by
the KRYPTOR ADAM12-S assay are somewhat higher
as compared to previous data [9,16,22,23]. None of the
assays which have been used for quantitative measure-
ment of ADAM12-S are traceable to international stan-
dard preparations of ADAM12-S, and therefore not
directly comparable. However, using the multiple of
Table 3 Empirical results
1 in 100 1 in 250
FPR
(95% CI)
DR
(95% CI)
FPR
(95% CI)
DR
(95% CI)
(i) maternal age, PAPP-A & free B-hCG 2.9
(1.5, 4.2)
72.2
(65.7, 78.7)
9.4
(7.0, 11.8)
86.2
(79.0, 93.3)
(ii) maternal age, PAPP-A, free B-hCG & ADAM12-S 2.6
(1.3, 3.9)
73.7
(67.7, 79.6)
9.3
(7.0, 11.7)
87.3
(80.4, 94.2)
(iii) maternal age, PAPP-A, free B-hCG & NT 0.6
(0.1, 1.2)
71.1
(61.8, 80.5)
2.8
(1.5, 4.1)
83.7
(75.7, 91.8)
(iv) maternal age, PAPP-A, free B-hCG, NT & ADAM12-S 0.7
(0.1, 1.3)
71.1
(61.8, 80.5)
2.6
(1.4, 3.8)
87.7
(80.4, 94.9)
(v) maternal age, PAPP-A & ADAM12-S 2.5
(1.4, 3.7)
56.8
(50.1, 63.5)
9.2
(6.9, 11.4)
73.7
(63.6, 83.8)
(vi) maternal age, PAPPA, ADAM12-S & NT 1.4
(0.6, 2.3)
75.1
(67.2, 83.1)
3.5
(2.2, 4.9)
81.4
(75.3, 87.6)
Results for a screening test including maternal age, PAPP-A and ADAM12-S, with and without NT. These results are empirical values, standardised to a reference
maternal age population (UK 2000 to 2002). Detection rates and false-positive rates for fetal trisomy 21 at fixed risk cut-offs of 1 in 100 and 1 in 250 are given.
Figures in brackets are 95% confidence intervals. Substantial decrease in DR when first trimester free B-hCG in (i) is replaced with ADAM12-S to give (v), with a
negligible decrease in FPR.
Substituting free B-hCG in the combined test (iii) for ADAM12-S to give (vi), gives a slightly higher DR and FPR at a risk cut-off of 1 in 100, and a slightly lower
DR and higher FPR at a risk cut-off of 1 in 250.
Table 4 Detection rate for a fixed false-positive rate:
Empirical results
DR
(95% CI)
(i) maternal age, PAPP-A & free B-hCG 76.5
(69.4, 83.7)
(ii) maternal age, PAPP-A, free B-hCG & ADAM12-S 73.7
(67.7, 79.6)
(iii) maternal age, PAPP-A, free B-hCG & NT 95.8
(94.6, 97.1)
(iv) maternal age, PAPP-A, free B-hCG, NT & ADAM12-S 92.9
(88.0, 97.8)
(v) maternal age, PAPP-A & ADAM12-S 61.6
(52.1, 71.1)
(vi) maternal age, PAPP-A, ADAM12-S & NT 83.2
(77.7, 88.8)
Results for first trimester screening test with and without ADAM12-S. These
results are empirical values, standardised to a reference maternal age
population (UK 2000 to 2002).
Detection rates for fetal trisomy 21 at a fixed false-positive rate of 5% are
given. Figures in brackets are 95% confidence intervals. Reduction in DR when
ADAM12-S is added to first trimester biochemistry and when ADAM12-S is
added to the combined test. Substantial reduction in DR when free B-hCG in
(i) is replaced with ADAM12-S to give (v) and when free B-hCG in (iii) is
replaced with ADAM12-S to give (vi).
Table 5 Modeled results
1 in 100 1 in 250
FPR DR FPR DR
(i) maternal age, PAPP-A & free B-hCG 4.6 77.7 9.8 87.3
(ii) maternal age, PAPP-A, free B-hCG &
ADAM12-S
4.6 77.6 9.8 87.2
(iii) maternal age, PAPP-A, free B-hCG & NT 2.5 87.0 5.1 91.9
(iv) maternal age, PAPP-A, free B-hCG, NT &
ADAM12-S
2.5 86.9 5.2 92.0
(v) maternal age, PAPP-A & ADAM12-S 5.4 72.3 11.9 84.3
(vi) maternal age, PAPP-A, ADAM12-S & NT 2.8 84.1 6.0 90.0
Results for a screening test including maternal age, PAPP-A and ADAM12-S,
with and without NT. Modeled detection rates and false-positive rates for fetal
trisomy 21 at fixed risk cut-offs of 1 in 100 and 1 in 250.
Increase in FPR and decrease in DR when free B-hCG in (i) is replaced with
ADAM12-S to give (v) and when free B-hCG in the combined test (iii) is
replaced with ADAM12-S to give (vi).
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median (MoM) to express the relative value of
ADAM12-S in serum samples from women with fetal
aneuploidy allows us to compare the results of the pre-
sent study with others. In the group of fetal trisomy 21
we found a median MoM in gestational week 8 of 0.66
increasing to around 0.9 in week 9-10. This is compar-
able to previous studies [5,6,13]. Together, these studies
include more than 340 cases of fetal trisomy 21 early in
the first trimester and strengthen the impression that
ADAM12-S is only moderately decreased early in the
first trimester, with the discriminatory value of this mar-
ker weakening with increasing gestational age in the first
trimester.
Our results support previous studies that have
described a positive correlation between ADAM12-S
and PAPP-A early in the first trimester [5,24,25].
Although ADAM12-S MoM is decreased in the first tri-
mester, the strong positive correlation between
ADAM12-S and PAPP-A in maternal serum negatively
affects the efficacy of ADAM12-S as a marker in first
trimester screening. Addition of ADAM12-S to the risk
calculation using the mixture model does not increase
the detection rate or lower the screen positive rate of
fetal trisomy 21, since the discriminatory value is already
encountered in the PAPP-A likelihood ratio. The pre-
sent results describing the lack of efficacy of ADAM12-
S on the detection rate and false positive rate of screen-
ing for fetal trisomy 21 in the first trimester emphasises
that ADAM12-S cannot generally improve the screening
for fetal trisomy 21 early in the first trimester.
Conclusion
According to the literature ADAM12-S has previously
been reported to significantly improve the detection rate
and false positive rate of first trimester screening for
fetal trisomy 21 [4,13]. However the present results and
a number of other large studies have failed to confirm
these data, and indicate that ADAM12-S is only moder-
ately decreased in cases of fetal trisomy, and does not
improve the performance of first trimester screening for
fetal trisomy 21.
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